Skip to main content
  • Register
  • Help
  • Contact us

Iovance Biotherapeutics Inc (IOVA) USD0.000041666

Sell:$30.60 Buy:$30.66 Change: $0.53 (1.70%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.53 (1.70%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.53 (1.70%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition to metastatic melanoma and metastatic cervical cancer, it is investigating TIL therapy and peripheral blood lymphocyte therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer and chronic lymphocytic leukemia.

Contact details

999 Skyway Rd Ste 150
United States
+1 (650) 2607120

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$4.57 billion
Shares in issue:
146.98 million
United States
US dollar

Key personnel

  • Iain Dukes
    Chairman of the Board
  • Maria Fardis
    President, Chief Executive Officer and Director
  • Jean-marc Bellemin
    Chief Financial Officer, Chief Principal Officer
  • Igor Bilinsky
    Chief Operating Officer
  • Michael Swartzburg
    Vice President - Finance
  • Frederick Vogt
    General Counsel, Corporate Secretary
  • Friedrich Graf Finckenstein
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.